- Home
- IONR vs SCPH Comparison
IONR vs SCPH Comparison
Compare IONR & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- SCPH
- Stock Information
- Founded
- IONR 2001
- SCPH 2013
- Country
- IONR Australia
- SCPH United States
- Employees
- IONR N/A
- SCPH N/A
- Industry
- IONR
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- SCPH Health Care
- Exchange
- IONR Nasdaq
- SCPH Nasdaq
- Market Cap
- IONR 171.1M
- SCPH 163.3M
- IPO Year
- IONR N/A
- SCPH 2017
- Fundamental
- Price
- IONR $4.20
- SCPH $5.40
- Analyst Decision
- IONR
- SCPH Strong Buy
- Analyst Count
- IONR 0
- SCPH 2
- Target Price
- IONR N/A
- SCPH $19.00
- AVG Volume (30 Days)
- IONR 8.7K
- SCPH 258.3K
- Earning Date
- IONR 01-01-0001
- SCPH 11-06-2024
- Dividend Yield
- IONR N/A
- SCPH N/A
- EPS Growth
- IONR N/A
- SCPH N/A
- EPS
- IONR N/A
- SCPH N/A
- Revenue
- IONR N/A
- SCPH $24,048,000.00
- Revenue This Year
- IONR N/A
- SCPH $195.62
- Revenue Next Year
- IONR N/A
- SCPH $145.07
- P/E Ratio
- IONR N/A
- SCPH N/A
- Revenue Growth
- IONR N/A
- SCPH 549.77
- 52 Week Low
- IONR $2.90
- SCPH $3.24
- 52 Week High
- IONR $6.50
- SCPH $7.55
- Technical
- Relative Strength Index (RSI)
- IONR 57.27
- SCPH 60.05
- Support Level
- IONR $3.76
- SCPH $4.97
- Resistance Level
- IONR $4.48
- SCPH $5.40
- Average True Range (ATR)
- IONR 0.28
- SCPH 0.23
- MACD
- IONR 0.03
- SCPH 0.00
- Stochastic Oscillator
- IONR 51.68
- SCPH 91.38
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S. based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.